
KU-55933 (ATM Kinase Inhibitor)
S1092
5~200mg
Brand
Selleckchem
Description
KU-55933 (ATM Kinase Inhibitor)
KU-55933 is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
Description | KU-55933 is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. | |||||
---|---|---|---|---|---|---|
Targets | ATM | ATM | ||||
IC50 | 13 nM | 2.2 nM (Ki) [1] | ||||
In vitro | KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2] | |||||
In vivo | Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3] | |||||
Features |
Protocol(Only for Reference)
Kinase Assay: [1]
Purified enzyme assays | ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out. |
---|
Cell Assay: [1]
Cell lines | U2OS cells |
---|---|
Concentrations | 10 μM |
Incubation Time | 2 hours |
Method | U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations. |
Animal Study: [3]
Animal Models | BALB/c nu/nu nude mice bearing LU1205 cells |
---|---|
Dosages | 10 μM |
Administration | |
Solubility | 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL |
References
Chemical Information
Download KU-55933 (ATM Kinase Inhibitor) SDF
Molecular Weight (MW) | 395.49 |
---|---|
Formula |
C21H17NO3S2 |
CAS No. | 587871-26-9 |
Storage | 3 years -20℃Powder |
---|---|
6 months-80℃in DMSO | |
Syonnyms | N/A |
Solubility (25°C) * | In vitro | DMSO | 33 mg/mL (83 mM) |
---|---|---|---|
Water | <1 mg/mL (<1 mM) | ||
Ethanol | <1 mg/mL (<1 mM) | ||
In vivo | 30% PEG400/0.5% Tween80/5% propylene glycol, | 30 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Chemical Name | 2-morpholino-6-(thianthren-1-yl)-4H-pyran-4-one |
---|
Preparing Stock Solutions
Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
---|---|---|---|---|
Mass(mg) | 0.39549 | 3.9549 | 7.9098 | 11.8647 |
Customer Reviews (4)
![]() Click to enlarge |
Rating |
|
Source | Cancer Discovery, 2012, 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck | |
Method | Western Blot | |
Cell Lines | HCC1937 cells | |
Concentrations | 10 uM | |
Incubation Time | 24 h | |
Results | As expected, KU-55933 led to a decrease in autophosphorylation of ATM ( Fig. 5A , third and fourth lane of each panel), and prevented the increase in H2AX phosphorylation seen in response to ionizing radiation. However, KU-55933 did not prevent the NVP-BKM120–induced induction of γ-H2AX, which was robust both at baseline and in response to ionizing radiation ( Fig. 5A , last lane of each panel), suggesting that an alternative kinase, such as DNA-PK, phosphorylates H2AX in response to PI3K inhibition. |
Product Citations (15)
-
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer. [Juvekar A, et al. Cancer Discov 2012;2(11):1048-63]
-
Defective chromatin recruitment and retention of NHEJ core components in human tumor cells expressing a Cyclin E fragment [Chatterjee P, et al. Nucleic Acids Res 2013;41(22):10157-69]
-
Systems Biology Approach Identifies the Kinase Csnk1a1 as a Regulator of the DNA Damage Response in Embryonic Stem Cells. [Jordi Carreras Puigvert, et al. Sci Signal 2013;6(259):ra5]
Application
Reactivity